| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Sebastian Schneeweiss | Q60162120 |
| P2093 | author name string | Michael Fralick | |
| Donald A Redelmeier | |||
| Elisabetta Patorno | |||
| Seoyoung C Kim | |||
| Dae Kim | |||
| P433 | issue | 3 | |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 155-163 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study | |
| P478 | volume | 170 |
| Q90116081 | Bone health in diabetes and prediabetes |
| Q92535991 | Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program |
| Q64244781 | Clinical implications of cardiovascular outcome trials in type 2 diabetes |
| Q96305104 | Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study |
| Q92925698 | Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus |
| Q64904716 | Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. |
| Q92259249 | Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials |
| Q92703271 | SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects |
| Q92853232 | SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects |
| Q64916602 | The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. |
Search more.